Biotechnology

Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

March 29, 2023 11:45 AM

Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 29, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX; Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 18,636,190 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to the exercise notices in respect of 1,738,136 A Warrants and...

Read more

CORRECTION FROM SOURCE: Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022

March 29, 2023 11:15 AM

The Company Announces Record Annual Revenue and Profit PLAINVIEW, NY / ACCESSWIRE / March 29, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022. "The Company recorded annual revenue of $80.0 million in fiscal year 2022, a growth of 5.9% over the prior year, and achieved an annual operating income of $7.0 million, an increase of 149.5% year-over-year. Net...

Read more

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022

March 29, 2023 9:00 AM

The Company Reports 5.9% Growth in Revenue and 149% Growth in Operating Income PLAINVIEW, NY / ACCESSWIRE / March 29, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022. "Our professional sales service segment continued exceptional growth, driving the Company's total revenue for fiscal year 2022 to $80.0 million, a growth of 5.9% over the fiscal year 2021....

Read more

Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

March 29, 2023 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT Continued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic programs for serious diseases Elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to be enrolled by AstraZeneca; clinical data anticipated by mid-2024 PRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis...

Read more

Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

March 28, 2023 12:55 PM

Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 28, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various US investors 7,473,095 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to the exercise notices in respect of 848,068 A Warrants and...

Read more

1nHealth Launches Site Advisory Board to Prioritize Site Voice

March 28, 2023 9:00 AM

The digital patient recruitment company tapped industry experts to monitor and provide feedback to best optimize its ability to serve study sites. ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Today, 1nHealth launched its Site Advisory Board, a consortium of research site owner-operators brought together to advise 1nHealth's recruitment efforts and technology development. The board will assist 1nHealth in executing on its goal of reducing site...

Read more

Biovica signs DiviTum(R) TKa Commercial Partner Agreement for Dutch and Polish Markets

March 28, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 28, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company has signed a commercial partnership with the European distributor TOROMEDICAL group for the commercialization of the DiviTumTKa test for clinical routine use in the Netherlands and Poland. Launch preparations commence immediately. Some 7,000 women are diagnosed with...

Read more

Levin Health Explains the Proposed Changes to Cannabis Laws That Are Gaining Support Within the Victorian Government

March 27, 2023 5:00 PM

Victorian MPs are pushing for the full legalisation of cannabis. Levin Health examines both sides of the argument MELBOURNE, AUSTRALIA / ACCESSWIRE / March 27, 2023 / Rachel Payne and David Ettershank, who both recently secured seats for the Legalise Cannabis Victoria party, are pushing for full legalisation of cannabis. Here, Levin Health, an Australian sports science company focused on researching medical cannabis products, weighs in. Levin...

Read more

Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

March 27, 2023 8:20 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs. Background Many cancers exhibit high levels of metabolic plasticity, i.e. the ability...

Read more

Tariq Hamoodi: Corporate Governance Concerns at Nanoco PLC

March 27, 2023 3:10 AM

SHAREHOLDERS RAISE SERIOUS CORPORATE GOVERNANCE CONCERNS AND DEMAND IMMEDIATE BOARD CHANGES AT NANOCO GROUP PLC LONDON, UK / ACCESSWIRE / March 27, 2023 / A group of shareholders ("Shareholder Group") in Nanoco Group Plc ("Nanoco"), led by Tariq Hamoodi, who holds an interest of over 4.23% of the outstanding share capital in Nanoco, are today making public a letter that was sent to the Board of Nanoco on 10 March 2023 outlining the Shareholder...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 27, 2023 3:10 AM

LUND, SWEDEN / ACCESSWIRE / March 27, 2023 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 27 April 2023 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by...

Read more

Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023

March 24, 2023 5:00 PM

BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS),a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host its year-end 2022 investor call on Wednesday, March 29, 2023 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access...

Read more

Midatech Pharma PLC Announces Results of General Meeting

March 24, 2023 8:00 AM

Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to...

Read more

Monitchem Holdco 2 S.A.: Thomas H. Ahrens will Become New CEO of CABB Group

March 24, 2023 2:20 AM

SULZBACH, GERMANY / PRATTEIN, SWITZERLAND / ACCESSWIRE / March24, 2023 / CABB Group today announced that Thomas H. Ahrens (61) will become the new CEO. He is currently CEO of the COMPO EXPERT Group, a leading global producer of specialty fertilisers for professional applications based in Münster (Germany). Ahrens will join CABB on 1 June 2023 and succeed Valerie Diele-Braun after a transition period of a few months. She will take on a new...

Read more

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

March 23, 2023 4:30 PM

TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The Fireside Chat discussion between Edesa's Chief Executive Officer Par...

Read more

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 4:00 PM

Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025 Updated clinical data from the Phase 1b advanced breast cancer trial with gedatolisib was presented at SABCS in December - median PFS was 42.3 months in treatment naïve advanced breast cancer patients Preclinical data reporting therapeutic effects of...

Read more

BioGX Candida Auris PCR Assay Adoption Accelerates

March 23, 2023 2:00 PM

BIRMINGHAM, AL / ACCESSWIRE / March 23, 2023 / BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety...

Read more

Oncolyze Launches an Equity Crowdfunding Campaign on StartEngine

March 23, 2023 9:15 AM

NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Oncolyze has launched a Regulation A+ ("Reg A") funding campaign to spread awareness of OM-301 among cancer patients, healthcare professionals, and the investment community. Reg A is a type of offering that allows anyone to invest in Oncolyze and receive shares in the company. The investment opportunity is being hosted by StartEngine and investments may be made in Oncolyze directly by visiting the...

Read more

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

March 23, 2023 7:35 AM

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Phase 1 clinical development - Closed the year with $13.1 million of cash expected to fund operations and drive pipeline development FRAMINGHAM, MA / ACCESSWIRE / March 23, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...

Read more

Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels

March 22, 2023 1:45 PM

NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform for the treatment of traumatic brain injuries (TBIs) and other nervous system pathologies, today announced that it has filed an International Patent Application at the International Bureau, for inventions of Therapeutic Polypseudorotaxane Hydrogels....

Read more